Diabetologists and Oncologists attitudes towards treating diabetes in the oncologic patient: Insights from an exploratory survey
Diabetes and cancer frequently coexist in the same subject, often having relevant effects on the management and prognosis of the oncologic patient. However, existing guidelines do not deal with many clinical issues in this setting appropriately. In evaluating the opinions of Diabetologists and Oncol...
Saved in:
Published in | Diabetes research and clinical practice Vol. 143; pp. 420 - 427 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier B.V
01.09.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Diabetes and cancer frequently coexist in the same subject, often having relevant effects on the management and prognosis of the oncologic patient. However, existing guidelines do not deal with many clinical issues in this setting appropriately. In evaluating the opinions of Diabetologists and Oncologists dealing with diabetes care in people with cancer, the Italian Association of Diabetologists (AMD) promoted a dedicated exploratory survey.
The survey was carried out through the web or handily delivered printed copies between October 2014 and April 2015, in Italy. It was composed of 27 questions intended to gather information on the characteristics of participants and to examine their clinical habits in this context, and participation was totally free and anonymous.
A total of 252 physicians participated in the survey. Diabetologists accounted for 51.1% of respondents. According to survey results, in spite of the presence of diabetes (or diabetic complications) worsening the outcome of cancer treatments, the counseling or intervention of a Diabetologist was only required for less than two-thirds of hospitalized patients. For subjects with a life expectancy of months, 80% of specialists considered a glycemic target of 120–250 mg/dL optimal whereas Oncologists were more likely to consider a range of 180–360 mg/dL for patients with a shorter life expectancy. Furthermore, 1 participant out of 3 indicated 1–4 measurements/day as the most appropriate frequency for blood glucose monitoring including in the palliative setting. Insulin was the therapy of choice for the majority of respondents albeit with different routes of administration.
This survey provides interesting preliminary data that could help facilitate and optimize the management of patients with cancer and diabetes, promoting the delivery of an organic answer to fragmented assistance, to potentially inappropriate behaviors, and to a tailored therapy in a context of particular clinical fragility. |
---|---|
AbstractList | Diabetes and cancer frequently coexist in the same subject, often having relevant effects on the management and prognosis of the oncologic patient. However, existing guidelines do not deal with many clinical issues in this setting appropriately. In evaluating the opinions of Diabetologists and Oncologists dealing with diabetes care in people with cancer, the Italian Association of Diabetologists (AMD) promoted a dedicated exploratory survey.
The survey was carried out through the web or handily delivered printed copies between October 2014 and April 2015, in Italy. It was composed of 27 questions intended to gather information on the characteristics of participants and to examine their clinical habits in this context, and participation was totally free and anonymous.
A total of 252 physicians participated in the survey. Diabetologists accounted for 51.1% of respondents. According to survey results, in spite of the presence of diabetes (or diabetic complications) worsening the outcome of cancer treatments, the counseling or intervention of a Diabetologist was only required for less than two-thirds of hospitalized patients. For subjects with a life expectancy of months, 80% of specialists considered a glycemic target of 120–250 mg/dL optimal whereas Oncologists were more likely to consider a range of 180–360 mg/dL for patients with a shorter life expectancy. Furthermore, 1 participant out of 3 indicated 1–4 measurements/day as the most appropriate frequency for blood glucose monitoring including in the palliative setting. Insulin was the therapy of choice for the majority of respondents albeit with different routes of administration.
This survey provides interesting preliminary data that could help facilitate and optimize the management of patients with cancer and diabetes, promoting the delivery of an organic answer to fragmented assistance, to potentially inappropriate behaviors, and to a tailored therapy in a context of particular clinical fragility. AIMSDiabetes and cancer frequently coexist in the same subject, often having relevant effects on the management and prognosis of the oncologic patient. However, existing guidelines do not deal with many clinical issues in this setting appropriately. In evaluating the opinions of Diabetologists and Oncologists dealing with diabetes care in people with cancer, the Italian Association of Diabetologists (AMD) promoted a dedicated exploratory survey.METHODSThe survey was carried out through the web or handily delivered printed copies between October 2014 and April 2015, in Italy. It was composed of 27 questions intended to gather information on the characteristics of participants and to examine their clinical habits in this context, and participation was totally free and anonymous.RESULTSA total of 252 physicians participated in the survey. Diabetologists accounted for 51.1% of respondents. According to survey results, in spite of the presence of diabetes (or diabetic complications) worsening the outcome of cancer treatments, the counseling or intervention of a Diabetologist was only required for less than two-thirds of hospitalized patients. For subjects with a life expectancy of months, 80% of specialists considered a glycemic target of 120-250 mg/dL optimal whereas Oncologists were more likely to consider a range of 180-360 mg/dL for patients with a shorter life expectancy. Furthermore, 1 participant out of 3 indicated 1-4 measurements/day as the most appropriate frequency for blood glucose monitoring including in the palliative setting. Insulin was the therapy of choice for the majority of respondents albeit with different routes of administration.CONCLUSIONSThis survey provides interesting preliminary data that could help facilitate and optimize the management of patients with cancer and diabetes, promoting the delivery of an organic answer to fragmented assistance, to potentially inappropriate behaviors, and to a tailored therapy in a context of particular clinical fragility. |
Author | Gallo, Marco Clemente, Gennaro Giorgini, Marisa Mancini, Marcello |
Author_xml | – sequence: 1 givenname: Gennaro surname: Clemente fullname: Clemente, Gennaro email: gennaro.clemente@cnr.it organization: IRPPS-Institute for Research on Population and Social Policies of the Italian National Research Council, Fisciano, Salerno, Italy – sequence: 2 givenname: Marisa surname: Giorgini fullname: Giorgini, Marisa organization: Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy – sequence: 3 givenname: Marcello surname: Mancini fullname: Mancini, Marcello organization: IBB-Institute of Biostructure and Bioimaging, of the Italian National Research Council, Naples, Italy – sequence: 4 givenname: Marco surname: Gallo fullname: Gallo, Marco organization: Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29596952$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkMFOGzEURa0KVALtJ7Tykk2mz57YM-mmQkBbpEhsYG157DfB0cRObQ9tdnw6JklhyerZ8rn3yeeUHPngkZAvDCoGTH5bVdbpLmKqOLC2Al7BbPaBTFjb8GnLeXNEJoVrd-cTcprSCgBkPRMfyQmfi7mcCz4hT1elBXMYwtKlnKj2lt5683bP2eXRYqI5_NXRlhlRZ-eX1O6S5cV5mh-QhkPM0E0B0Ofv9MYnt3woNX0M69JN8d9mCFHnELc0jfERt5_Ica-HhJ8P84zc_7y-u_w9Xdz-urm8WExNLUWe9kzXNbYdCmF0YwAsMNF1tmkktIKBKXdpjLZcAheGsb6zVpq-5gxKStdn5Hzfu4nhz4gpq7VLBodBewxjUhw4zNqaN7KgYo-aGFKK2KtNdGsdt4qBepGvVuogX73IV8BVkV9yXw8rxm6N9jX133YBfuwBLB99dBhVMkWUQesimqxscO-seAanhp4K |
CitedBy_id | crossref_primary_10_1007_s00520_023_07927_9 crossref_primary_10_1016_j_diabres_2019_04_036 crossref_primary_10_1136_bmjopen_2018_028604 crossref_primary_10_1007_s10389_020_01200_7 crossref_primary_10_1080_08880018_2023_2295454 crossref_primary_10_1177_26350106231153073 |
Cites_doi | 10.1016/j.jpainsymman.2006.03.011 10.1191/0269216306pm1128oa 10.2337/diaspect.19.3.157 10.1007/s00592-016-0839-z 10.1007/s00125-014-3186-z 10.1111/j.1365-2354.2005.00564.x 10.1016/j.metabol.2017.09.013 10.4158/EP13248.CS 10.1093/qjmed/hcu218 10.1002/cncr.20071 10.1002/jso.24133 10.1016/S0885-3924(96)00326-0 10.1177/1049909114533140 |
ContentType | Journal Article |
Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
CorporateAuthor | on behalf of the AMD-Associazione Medici Diabetologi ‘Diabetes and Cancer’ working group AMD - Associazione Medici Diabetologi 'Diabetes, Cancer' working group |
CorporateAuthor_xml | – name: on behalf of the AMD-Associazione Medici Diabetologi ‘Diabetes and Cancer’ working group – name: AMD - Associazione Medici Diabetologi 'Diabetes, Cancer' working group |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.diabres.2018.02.044 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1872-8227 |
EndPage | 427 |
ExternalDocumentID | 10_1016_j_diabres_2018_02_044 29596952 S0168822717315929 |
Genre | Journal Article Review |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29F 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFNM ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AENEX AEVXI AFKWA AFRHN AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HZ~ IHE J1W KOM LCYCR LZ1 M29 M41 MO0 N9A O-L O9- OAUVE OB0 ON- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SEL SES SEW SPCBC SSH SSU SSZ T5K WUQ X7M Z5R ZA5 ZGI ~G- AAXKI AFCTW AKRWK NPM 0SF AAYXX ADVLN AFJKZ CITATION 7X8 |
ID | FETCH-LOGICAL-c365t-f1a33e8be55ca7c00d015bbd77608510cd016ccad26025c11fbdd6cf32108bea3 |
IEDL.DBID | AIKHN |
ISSN | 0168-8227 |
IngestDate | Fri Aug 16 08:27:20 EDT 2024 Thu Sep 26 16:01:49 EDT 2024 Wed Oct 16 01:00:47 EDT 2024 Fri Feb 23 02:26:49 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Antidiabetic drugs SMBG Survey Clinical management Type 2 diabetes mellitus Tumors clinical management type 2 diabetes mellitus survey tumors antidiabetic drugs |
Language | English |
License | Copyright © 2018 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c365t-f1a33e8be55ca7c00d015bbd77608510cd016ccad26025c11fbdd6cf32108bea3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
PMID | 29596952 |
PQID | 2020483276 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_2020483276 crossref_primary_10_1016_j_diabres_2018_02_044 pubmed_primary_29596952 elsevier_sciencedirect_doi_10_1016_j_diabres_2018_02_044 |
PublicationCentury | 2000 |
PublicationDate | 2018-09-01 |
PublicationDateYYYYMMDD | 2018-09-01 |
PublicationDate_xml | – month: 09 year: 2018 text: 2018-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Ireland |
PublicationPlace_xml | – name: Ireland |
PublicationTitle | Diabetes research and clinical practice |
PublicationTitleAlternate | Diabetes Res Clin Pract |
PublicationYear | 2018 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Ranc, Jørgensen, Friis, Carstensen (b0010) 2014; 57 AMD (Italian Association of Diabetologists) Working Group on “Diabetes and Cancer”. Jacob, Chowdhury (b0060) 2015; 108 Poulson (b0055) 1997; 13 Pan Birmingham Cancer Network: Guideline for the Management of Diabetes Mellitus in Palliative Medicine. Weiser, Cabanillas, Konopleva, Thomas, Pierce, Escalante (b0015) 2004; 100 Mateo J, Castro F, Olmos D, on behalf of the European Society for Medical Oncology. Cancer treatment in patients with diabetes. In 2013 ESMO Handbook on cancer treatment in special clinical situations: Edit. ESMO Press; 2013, p- 72–88. Quinn, Hudson, Dunning (b0070) 2006; 32 Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, Einhorn D, Garber AJ, Grunberger G, Harrell RM, Gagel RF, Lebovitz HE, McGill JB, Hennekens CH. Diabetes and cancer an AACE/ACE consensus statement. Endocr Pract. 2013 Jul-Aug;19(4), pp. 675–93 [accessed August 2017]. Diabetes UK: End of Life Diabetes Care - Clinical Care Recommendations. . Psarakis (b0025) 2006; 19 Lee, Yoon, Han, Cho, Choi, Jang (b0020) 2016; 113 Dionisio, Giardini, De Cata, Pirali, Rossi, Negri (b0080) 2015; 32 Gallo, Muscogiuri, Felicetti, Faggiano, Trimarchi, Arvat (b0085) 2018; 78 McCoubrie, Jeffrey, Paton, Dawes (b0065) 2005; 14 Gallo, Gentile, Arvat, Bertetto, Clemente (b0045) 2016; 53 Ford-Dunn, Smith, Quin (b0075) 2006; 20 Rete Oncologica Piemonte-Valle d’Aosta. Protocollo per la gestione del paziente oncologico con diabete mellito. 10.1016/j.diabres.2018.02.044_b0005 Lee (10.1016/j.diabres.2018.02.044_b0020) 2016; 113 Ranc (10.1016/j.diabres.2018.02.044_b0010) 2014; 57 Quinn (10.1016/j.diabres.2018.02.044_b0070) 2006; 32 McCoubrie (10.1016/j.diabres.2018.02.044_b0065) 2005; 14 10.1016/j.diabres.2018.02.044_b0090 Psarakis (10.1016/j.diabres.2018.02.044_b0025) 2006; 19 10.1016/j.diabres.2018.02.044_b0050 Weiser (10.1016/j.diabres.2018.02.044_b0015) 2004; 100 Dionisio (10.1016/j.diabres.2018.02.044_b0080) 2015; 32 10.1016/j.diabres.2018.02.044_b0030 10.1016/j.diabres.2018.02.044_b0040 Poulson (10.1016/j.diabres.2018.02.044_b0055) 1997; 13 Gallo (10.1016/j.diabres.2018.02.044_b0085) 2018; 78 Ford-Dunn (10.1016/j.diabres.2018.02.044_b0075) 2006; 20 Gallo (10.1016/j.diabres.2018.02.044_b0045) 2016; 53 Jacob (10.1016/j.diabres.2018.02.044_b0060) 2015; 108 10.1016/j.diabres.2018.02.044_b0035 |
References_xml | – volume: 113 start-page: 203 year: 2016 end-page: 208 ident: b0020 article-title: Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma publication-title: J Surg Oncol contributor: fullname: Jang – volume: 78 start-page: 141 year: 2018 end-page: 154 ident: b0085 article-title: Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes publication-title: Metabolism contributor: fullname: Arvat – volume: 19 start-page: 157 year: 2006 end-page: 162 ident: b0025 article-title: Clinical challenges in caring for patients with diabetes and cancer publication-title: Diabetes Spectrum contributor: fullname: Psarakis – volume: 14 start-page: 244 year: 2005 end-page: 248 ident: b0065 article-title: Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines publication-title: Eur J Cancer Care (Engl) contributor: fullname: Dawes – volume: 57 start-page: 927 year: 2014 end-page: 934 ident: b0010 article-title: Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment publication-title: Diabetologia contributor: fullname: Carstensen – volume: 108 start-page: 443 year: 2015 end-page: 448 ident: b0060 article-title: Management of diabetes in patients with cancer publication-title: QJM contributor: fullname: Chowdhury – volume: 53 start-page: 515 year: 2016 end-page: 524 ident: b0045 article-title: Diabetology and oncology meet in a network model: union is strength publication-title: Acta Diabetol contributor: fullname: Clemente – volume: 20 start-page: 197 year: 2006 end-page: 203 ident: b0075 article-title: Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK publication-title: Palliat Med contributor: fullname: Quin – volume: 32 start-page: 275 year: 2006 end-page: 286 ident: b0070 article-title: Diabetes management in patients receiving palliative care publication-title: J Pain Symptom Manage contributor: fullname: Dunning – volume: 100 start-page: 1179 year: 2004 end-page: 1185 ident: b0015 article-title: Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen publication-title: Cancer contributor: fullname: Escalante – volume: 13 start-page: 339 year: 1997 end-page: 346 ident: b0055 article-title: The management of diabetes in patients with advanced cancer publication-title: J Pain Symptom Manage contributor: fullname: Poulson – volume: 32 start-page: 588 year: 2015 end-page: 593 ident: b0080 article-title: Diabetes management in end of life: a preliminary report stemming from clinical experience publication-title: Am J Hosp Palliat Care contributor: fullname: Negri – volume: 32 start-page: 275 year: 2006 ident: 10.1016/j.diabres.2018.02.044_b0070 article-title: Diabetes management in patients receiving palliative care publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2006.03.011 contributor: fullname: Quinn – ident: 10.1016/j.diabres.2018.02.044_b0035 – volume: 20 start-page: 197 issue: 3 year: 2006 ident: 10.1016/j.diabres.2018.02.044_b0075 article-title: Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK publication-title: Palliat Med doi: 10.1191/0269216306pm1128oa contributor: fullname: Ford-Dunn – volume: 19 start-page: 157 issue: 3 year: 2006 ident: 10.1016/j.diabres.2018.02.044_b0025 article-title: Clinical challenges in caring for patients with diabetes and cancer publication-title: Diabetes Spectrum doi: 10.2337/diaspect.19.3.157 contributor: fullname: Psarakis – ident: 10.1016/j.diabres.2018.02.044_b0030 – volume: 53 start-page: 515 year: 2016 ident: 10.1016/j.diabres.2018.02.044_b0045 article-title: Diabetology and oncology meet in a network model: union is strength publication-title: Acta Diabetol doi: 10.1007/s00592-016-0839-z contributor: fullname: Gallo – volume: 57 start-page: 927 year: 2014 ident: 10.1016/j.diabres.2018.02.044_b0010 article-title: Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment publication-title: Diabetologia doi: 10.1007/s00125-014-3186-z contributor: fullname: Ranc – volume: 14 start-page: 244 issue: 3 year: 2005 ident: 10.1016/j.diabres.2018.02.044_b0065 article-title: Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines publication-title: Eur J Cancer Care (Engl) doi: 10.1111/j.1365-2354.2005.00564.x contributor: fullname: McCoubrie – volume: 78 start-page: 141 year: 2018 ident: 10.1016/j.diabres.2018.02.044_b0085 article-title: Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes publication-title: Metabolism doi: 10.1016/j.metabol.2017.09.013 contributor: fullname: Gallo – ident: 10.1016/j.diabres.2018.02.044_b0090 – ident: 10.1016/j.diabres.2018.02.044_b0050 – ident: 10.1016/j.diabres.2018.02.044_b0005 doi: 10.4158/EP13248.CS – volume: 108 start-page: 443 year: 2015 ident: 10.1016/j.diabres.2018.02.044_b0060 article-title: Management of diabetes in patients with cancer publication-title: QJM doi: 10.1093/qjmed/hcu218 contributor: fullname: Jacob – volume: 100 start-page: 1179 issue: 6 year: 2004 ident: 10.1016/j.diabres.2018.02.044_b0015 article-title: Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen publication-title: Cancer doi: 10.1002/cncr.20071 contributor: fullname: Weiser – volume: 113 start-page: 203 issue: 2 year: 2016 ident: 10.1016/j.diabres.2018.02.044_b0020 article-title: Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma publication-title: J Surg Oncol doi: 10.1002/jso.24133 contributor: fullname: Lee – ident: 10.1016/j.diabres.2018.02.044_b0040 – volume: 13 start-page: 339 year: 1997 ident: 10.1016/j.diabres.2018.02.044_b0055 article-title: The management of diabetes in patients with advanced cancer publication-title: J Pain Symptom Manage doi: 10.1016/S0885-3924(96)00326-0 contributor: fullname: Poulson – volume: 32 start-page: 588 issue: 6 year: 2015 ident: 10.1016/j.diabres.2018.02.044_b0080 article-title: Diabetes management in end of life: a preliminary report stemming from clinical experience publication-title: Am J Hosp Palliat Care doi: 10.1177/1049909114533140 contributor: fullname: Dionisio |
SSID | ssj0006345 |
Score | 2.3117912 |
SecondaryResourceType | review_article |
Snippet | Diabetes and cancer frequently coexist in the same subject, often having relevant effects on the management and prognosis of the oncologic patient. However,... AIMSDiabetes and cancer frequently coexist in the same subject, often having relevant effects on the management and prognosis of the oncologic patient.... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 420 |
SubjectTerms | Antidiabetic drugs Clinical management SMBG Survey Tumors Type 2 diabetes mellitus |
Title | Diabetologists and Oncologists attitudes towards treating diabetes in the oncologic patient: Insights from an exploratory survey |
URI | https://dx.doi.org/10.1016/j.diabres.2018.02.044 https://www.ncbi.nlm.nih.gov/pubmed/29596952 https://search.proquest.com/docview/2020483276 |
Volume | 143 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTtwwEB3BIlW9VLS0ZYEiV-KaXSd2nIQbQqClFXAAJG6WEzvV7sGLSLYSF8SnM5M4IA6oUi-JHGUSy-OM33jeTAAOYkvpnZmNuFVVJEvnojx2HA8xwgVRC9nV7jy_ULMb-es2vV2D4yEXhmiVwfb3Nr2z1uHKNIzm9G4-n14hWEF4mFAYGdfkpFiHDVyOpBzBxtHZ79nFi0FWQvZMRpVHJPCayDNdTGiLEx1bInnlXfVOKd9bot6DoN1SdLoJnwKGZEd9Nz_DmvNf4MN5iJJvwVNPc1n22T0NM96yS1-9tlviB1jXsLYjzeK5g47-Dxu2YtncM4SGbBnEKhYKsB6yM9-QQ98wykzBZzPX0fi6aD1rVvd_3cNXuDk9uT6eReFPC1ElVNpGdWyEcHnp0rQyWcW5RZRQljbLFEEyXmFboa4tej9JWsVxXVrUbU0JQChlxDcY-aV328AEftC2MM7kiZOm5iW67gQjjeK14NaOYTIMrr7rC2rogWm20EEbmrSheaJRG2PIBxXoNzNDo9H_l-jPQWUavxoKhRjvliu6iQoWiyRTY_je6_KlN0mRFqpIk53_f_EufKRWz0Xbg1F7v3I_ELy05T6sTx7j_TBFnwFZUfFE |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTtwwEB1RKrVcEKWlXaDFlXrNrhMnTsKtQkVLy9JDQeJmObGDloMXkSwSF8SnM-M4XfWAkHpJ5MROLI8zfuN5MwH4FhsK78xNxI2so7SyNipiy_EQI1wQjUh97s7ZmZxepD8vs8s1OBpiYYhWGXR_r9O9tg5XJmE0Jzfz-eQPghWEhwm5kXFNTspX8JrQAPG6xg8rnocUac9jlEVE1VdhPJPrMW1wollLFK_C5-5M0-cWqOcAqF-IjrdgMyBI9r3v5DtYs24b3syCj_w9PPYkl0Uf29My7Qz77epVuSN2gLEt6zxlFs8eOLorNmzEsrljCAzZIjSrWUi_eshOXEvmfMsoLgWfzawn8XlfPWuXt3f2_gNcHP84P5pG4T8LUS1k1kVNrIWwRWWzrNZ5zblBjFBVJs8lATJeY1mipA3aPklWx3FTGZRsQ-E_2EqLHVh3C2c_ARP4OZtSW10kNtUNr9BwJxCpJW8EN2YE42Fw1U2fTkMNPLNrFaShSBqKJwqlMYJiEIH6Z14oVPkvNf06iEzhN0OOEO3sYkmVKF2xSHI5go-9LP_2JimzUpZZsvv_Lz6At9Pz2ak6PTn7tQcbdKdnpe3Dene7tJ8RxnTVFz9NnwCEFPIZ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diabetologists+and+Oncologists+attitudes+towards+treating+diabetes+in+the+oncologic+patient%3A+Insights+from+an+exploratory+survey&rft.jtitle=Diabetes+research+and+clinical+practice&rft.au=Clemente%2C+Gennaro&rft.au=Giorgini%2C+Marisa&rft.au=Mancini%2C+Marcello&rft.au=Gallo%2C+Marco&rft.date=2018-09-01&rft.pub=Elsevier+B.V&rft.issn=0168-8227&rft.eissn=1872-8227&rft.volume=143&rft.spage=420&rft.epage=427&rft_id=info:doi/10.1016%2Fj.diabres.2018.02.044&rft.externalDocID=S0168822717315929 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-8227&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-8227&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-8227&client=summon |